299660.KQ
Cellid, Co., Ltd. [299660.KQ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
299660.KQ Stock Summary
Top 10 Correlated ETFs
299660.KQ
Top 10 Correlated Stocks
299660.KQ
In the News
299660.KQ Financial details
Company Rating
-
Market Cap
40.69B
Income
-
Revenue
-
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
19 Mar 2019
P/E
-2.08
Forward P/E
-
PEG
-
P/S
89.46
P/B
2.83
P/C
-
P/FCF
-
Quick Ratio
0.29
Current Ratio
0.68
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
22.54%
SMA50
-22.39%
SMA100
-36.41%
Inst Own
-
Inst Trans
-
ROA
-68%
ROE
-101%
ROC
-0.7%
Gross Margin
31%
Oper. Margin
-2712%
Profit Margin
-4380%
Payout
-
Shs Outstand
9.56M
Shs Float
7.69M
-
-
-
-
Target Price
-
52W Range
3100.0-14900.0
52W High
-69.7%
52W Low
+45.65%
RSI
60.44
Rel Volume
0.9
Avg Volume
132.33K
Volume
118.81K
Perf Week
14.02%
Perf Month
17.58%
Perf Quarter
-47.07%
Perf Half Y
-46.94%
-
-
-
-
Beta
1.462
-
-
Volatility
97.19%, 376.46%
Prev Close
5.37%
Price
4515
Change
-1.74%
Company Profile
- Volume Average 132.33K
- Market Capitalization 40.69B
- CEO Yuil Kang Chang
- Headquarters Seoul,KR
- IPO Date 2019-02-19
-
Website
http://www.cellid.co.kr 
Cellid, Inc. develops immunothetherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and genital cancer with human papilloma virus antigen; BVAC-B for gastric, ovarian, lung, and pancreatic cancer with HER-2/neu antigen; and BVAC-P for prostate, urinary tract, and brain cancer with PAP/PSMA antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; and BVAC-Neo, a customized immunotherapeutic vaccine. Cellid, Inc. was founded in 2006 and is based in Seoul, South Korea.
